Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNCT with BPA-fructose in Metastatic Melanoma
NCT00085059Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2004
- Primary completion
- Oct 2006
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of boronophenylalanine + fructose in melanoma, sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Best response to treatment at 8 weeks and Objective local response. Started Apr 2004; status: terminated.
02
Drugs
boronophenylalanine + fructose
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00085059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085059.